Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Epidemiology/Health Services/Psychosocial Research

Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians

  1. Chamukuttan Snehalatha, MSC, DSC1,
  2. Bheekamchand Mukesh, MBBS1,
  3. Mary Simon, BSC1,
  4. Vijay Viswanathan, MD, PHD1,
  5. Steven M. Haffner, MD2 and
  6. Ambady Ramachandran, MD, PHD, FRCP1
  1. 1Diabetes Research Centre, M.V. Hospital for Diabetes, WHO Collaborating Centre for Research, Education & Training in Diabetes, Royapuram, Chennai, India
  2. 2Division of Clinical Epidemiology, Department of Medicine, University of Texas Health Science Center of San Antonio, San Antonio, Texas
  1. Address correspondence and reprint requests to Prof. A. Ramachandran, Director, Diabetes Research Centre, M.V. Hospital for Diabetes & WHO Collaborating Centre for Research, Education & Training in Diabetes, 4 Main Rd., Royapuram, Chennai 600 013, India. E-mail: ramachandran{at}vsnl.com
Diabetes Care 2003 Dec; 26(12): 3226-3229. https://doi.org/10.2337/diacare.26.12.3226
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading

Abstract

OBJECTIVE—Adiponectin, secreted by fat cells, has regulatory functions on energy metabolism. Its low levels are predictive of future development of diabetes. Because no studies on the regulatory role of adiponectin in glucose homeostasis in Asian Indians exist, this analysis was performed to determine the prospective association of adiponectin and diabetes in subjects with impaired glucose tolerance (IGT).

RESEARCH DESIGN AND METHODS—Baseline values of plasma adiponectin, results of anthropometry, fasting and 2-h plasma glucose levels, HbA1c, results of lipid profile, and insulin resistance were analyzed in 91 subjects with IGT (53 men and 38 women) in a primary prevention study. Reassessment of glucose tolerance was performed during 1-year review. The predictive nature of adiponectin for development of diabetes was assessed using univariate and multiple logistic regression analyses. A control group comprising healthy, normoglycemic individuals was used for comparison.

RESULTS—At follow-up, diabetes had developed in 25 of the 91 study subjects. The mean baseline adiponectin level was lower in the diabetic subjects than in the nondiabetic subjects (11.3 ± 5.5 vs. 16.7 ± 7.6 μg/ml, P = 0.0017). Low adiponectin level was a strong predictor of future development of diabetes, and HbA1c also showed a positive predictive association. Women had higher adiponectin levels (16.4 ± 6.1 μg/ml) than men (13.9 ± 7.6 μg/ml) (P = 0.035).

CONCLUSIONS—In Asian Indians, low plasma adiponectin level was predictive of future development of diabetes.

  • IGT, impaired glucose tolerance
  • NGT, normal glucose tolerance
  • OGTT, oral glucose tolerance test

Adiponectin is a hormone produced solely by adipocytes and is a regulator of glucose and energy homeostasis (1,2). Low plasma adiponectin concentration is associated with a decrease in whole-body insulin sensitivity in humans (3–5) and has been shown to be predictive of future development of diabetes in a few studies (6–8).

Asian Indians have a high risk of diabetes and have an obesity phenotype characterized by lean BMI, central obesity, and high body fat percentage. In addition, Asian Indians also have high degree of insulin resistance (9,10). The role of adiponectin in regulating the complex mechanisms of insulin action and glucose homeostasis has not been studied in this population.

Subjects with persistent impaired glucose tolerance (IGT) on two oral glucose tolerance tests (OGTTs) were identified in a population screening to prospectively study the feasibility of primary prevention of type 2 diabetes and to assess the efficacy of lifestyle modification and treatment with metformin as preventive strategies (11). This cohort of urban Asian Indians are being followed regularly to look for the end points, viz., occurrence of diabetes or cardiovascular diseases. Glycemic status had been reassessed after 1 year by repeat OGTT. The baseline data of the subjects who had nonpharmacological intervention and had undergone review OGTT at 1 year were used in this analysis. The aims of study were 1) to determine the plasma adiponectin concentration in healthy Asian Indians and 2) to determine whether a prospective association existed between plasma adiponectin and type 2 diabetes in this population.

RESEARCH DESIGN AND METHODS

The study group was selected from a cohort of subjects with IGT being followed for 3 years in the Indian Diabetes Prevention Program (IDPP), which studies the effect of intervention measures to prevent deterioration of glucose intolerance (11). A total of 531 subjects with IGT were randomized to four groups: group 1 received standard care, group 2 was instructed in a diet modification and exercise program, group 3 received metformin, and group 4 received advice on lifestyle modification in addition to metformin. The study protocol was approved by the ethical committee of the institution, and written informed consent was obtained from each participant. All participants are being followed regularly with annual OGTTs. The 91 subjects (53 men and 38 women) selected for the study were from groups 1 and 2 only, i.e., they did not have any pharmacologic intervention. Glucose tolerance status was reassessed by repeat OGTT at 1 year, based on the World Health Organization (WHO) criteria (12). During the repeat OGTT at 1 year, 34 subjects had normal glucose tolerance (NGT), 32 subjects had IGT, and 25 had diabetes. Hitherto, subjects are referred to as the NGT, IGT, or diabetic subgroups. The baseline parameters in the subgroups were analyzed. The mean age was 45.2 ± 5.3 years, and mean BMI was 26.3 ± 3.5 kg/m2. A group of age- and BMI-matched, apparently healthy subjects having NGT on OGTT were selected as the control group (n = 50; 20 men and 30 women; mean age 45.7 ± 11.3 years and mean BMI 24.5 ± 5.4 kg/m2).

All study subjects had baseline records of age, BMI, waist circumference, and percentage of body fat (bioimpedance method). Measurement of HbA1c (immunoturbidimetric method), fasting and 2-h plasma glucose levels, and plasma lipid levels was performed using standard enzymatic procedures (9). In the total group of 91 subjects with IGT, fasting plasma insulin concentrations were measured by radioimmunoassay. Reagent kits supplied by Diasorin (Saluggia, Italy) were used (assay sensitivity <4 μg/ml at 95% CI). Intra-assay and interassay coefficients of variation were <10%. Insulin resistance was calculated using homeostasis model assessment (HOMA) (13). Baseline fasting plasma adiponectin levels were measured in the control and IGT subjects by radioimmunoassay using reagent kits provided by Linco Research (St. Louis, MO). This assay uses 125I-labeled adiponectin and an anti-adiponectin rabbit antiserum to measure adiponectin concentrations by the double-antibody/polyethylene glycol (PEG) technique. Standards over the range of 1–200 ng/ml were prepared using recombinant human adiponectin. All plasma samples were diluted 1:200, yielding an effective range of 0.2–40 μg/ml. The intra-assay and interassay coefficients of variation at adiponectin concentrations in the range of 3–15 μg/ml are 2.0–6.8 and 7.1–9.6%, respectively.

EDTA blood samples were stored in ice, and plasma aliquots were separated within 3 h and stored frozen at −70°C until the assay had been completed. Repeated freezing and thawing was avoided.

Statistical analysis

The values are reported as means and SDs. Unpaired Student’s t test was used for group comparisons. P < 0.05 was considered significant. Adiponectin values in all subjects with IGT (n = 91) were divided into tertiles. Percentage distribution of adiponectin in the NGT, IGT, and diabetic subgroups in the tertiles was calculated.

χ2 analysis was performed to assess the differences in proportions between groups. Multiple logistic regression analysis with forward stepwise addition was used to determine the association of variables, including adiponectin level, with future development of diabetes. Data were analyzed using the SPSS 4.0.1 statistical package (SPSS, Chicago, IL).

RESULTS

Plasma adiponectin levels were similar in the control subjects (14.9 ± 5.9 μg/ml) and those with IGT (15.2 ± 7.5 μg/ml). In the control group, women had higher adiponectin levels (16 ± 4.8 μg/ml) than men (13.4 ± 7.1 μg/ml), but the difference did not reach statistical significance. Because the values were similar in the control and IGT groups, sex difference in adiponectin was assessed in the total group. Women had higher mean values (16.4 ± 6.1 μg/ml; n = 68) than men (13.9 ± 7.6 μg/ml; n = 73) (P = 0.035).

Comparison of the baseline variables in the diabetic and nondiabetic (NGT + IGT) subgroups is shown in Table 1. Because adiponectin levels were similar in the NGT and IGT subgroups (16.9 ± 8.2 and 16.6 ± 7.1 μg/ml, respectively), these subgroups were combined and shown as the nondiabetic group. All parameters were similar in nondiabetic and diabetic groups, except for waist circumference. Diabetic men had higher waist circumference than nondiabetic men. Adiponectin levels were significantly lower in subjects in whom diabetes developed (11.3 ± 5.5 vs. 16.7 ± 7.6 μg/ml, P = 0.002).

There was no significant sex difference in the rate of conversion to diabetes. The percentage of men in the prospective diabetic and nondiabetic groups was 64 and 56%, respectively (χ2 = 0.2, P = 0.65). The percentage distribution of the diabetic and nondiabetic groups in tertiles of adiponectin is shown in Fig. 1. The tertile values of adiponectin (μg/ml) were as follows: tertile 1 = 3.0–9.9; tertile 2 = 10.0–18.7; tertile 3 = 18.8–43.7.

A higher percentage of prospective diabetic subjects were in tertile 1 (56%) compared with the nondiabetic subjects (24.2%) (λ2 = 6.9, P = 0.009).

In the multiple logistic regression analysis (Table 2), the factors predictive of future development of diabetes were baseline HbA1c and low plasma adiponectin concentration.

CONCLUSIONS

The most important finding of this study was that low adiponectin concentration was predictive of prospective diabetes. We had studied a cohort of subjects with IGT who were at high risk for diabetes by virtue of increased 2-h plasma glucose level. Among these subjects, low adiponectin level was found to be a strong independent predictor of diabetes. Insulin resistance was not significantly different between the prospective diabetic and nondiabetic groups. This is the first study of the predictive value of low adiponectin level in a non-white population. The predictive nature of low concentrations of adiponectin for diabetes has been demonstrated in Pima Indians (7) and in the European Prospective Investigation into Cancer and Nutrition (EPIC) study in Germany (8). Lower concentrations of adiponectin found in the above studies, when compared with the values in our study group, may be partly related to the differences in BMI. As mentioned earlier, there may also be population-based differences in the adiponectin concentrations.

Our study shows that adiponectin concentrations in Asian Indians were similar to the values in the Native Canadian population (14). Both populations are experiencing a rapid increase in diabetes and cardiovascular disease. Valsamakis et al. (15) found that obese Indo-Asians in the U.K. had lower median levels of adiponectin than a matched group of Caucasians. The difference in the values between this study and the present study may be possibly related to the higher BMI of subjects in the U.K. study. Cnop et al. (16) reported lower levels in Americans with BMI comparable to the subjects in our study group. It is likely that concentrations of adiponectin may also vary in different populations.

Although we did not find an independent association between the abdominal obesity indicated by increased waist circumference, the possibility that adiponectin is closely related to intra-abdominal fat and plays an important role in the relationship between visceral adiposity and insulin resistance was not excluded. Elegant studies by Cnop et al. (16) in healthy subjects have shown evidence of such a relationship between intra-abdominal fat and adiponectin.

We observed a sex dimorphism in adiponectin in Asian Indians: women had higher levels than men. Similar reports have been published by some (4,16–18), whereas a few others have failed to observe the sex difference (19,20). The impact of female sex on adiponectin concentrations was shown to be independent of age, BMI, abdominal fat, and insulin sensitivity in healthy subjects (16).

In summary, we have observed that low adiponectin concentration is a strong independent predictor of future development of diabetes in subjects with IGT. Adiponectin may have a central role in the pathogenesis of type 2 diabetes. More detailed studies in Asian Indians are warranted to understand the complex relation between insulin sensitivity, body fat distribution, and adiponectin concentration.

Figure 1—
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1—

Comparison of the percentage distribution of subjects in whom diabetes developed and nondiabetic subjects in the tertiles of adiponectin (μg/ml): tertile 1 = 3.0–9.9; tertile 2 = 10.0–18.7; tertile 3 = 18.8–43.7. Baseline values of adiponectin were analyzed.

View this table:
  • View inline
  • View popup
Table 1—

Baseline anthropometric and biochemical parameters in the group that developed diabetes in comparison with the nondiabetic group

View this table:
  • View inline
  • View popup
Table 2—

Results of multiple logistic regression analysis (diabetic versus nondiabetic group)

Acknowledgments

We thank Kumpatla Satyavani and Selvaraj Sivasankari for help in biochemical analysis and Kavessary Vettath Bindhu for secretarial assistance.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted August 26, 2003.
    • Received June 5, 2003.
  • DIABETES CARE

References

  1. ↵
    Saltiel AR: You are what you secrete. Nat Med 7:887–888, 2001
    OpenUrlCrossRefPubMedWeb of Science
  2. ↵
    Havel PJ: Control of energy homeostasis and insulin action by adipocyte hormones: leptin, acylation stimulating protein, and adiponectin. Curr Opin Lipidol 13:51–59, 2002
    OpenUrlCrossRefPubMedWeb of Science
  3. ↵
    Tschritter O, Fritsche A, Thamer C, Haap M, Shirkavand F, Rahe S, Staiger H, Maerker E, Haring H, Stumvoll M: Plasma Adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes 52:239–243, 2003
    OpenUrlAbstract/FREE Full Text
  4. ↵
    Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S, Malatino LS, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Buemi M, Nicocia G, Tanaka S, Duchi N, Kihara S, Funahashi T, Matsuzawa Y: Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol 13:134–141, 2002
    OpenUrlAbstract/FREE Full Text
  5. ↵
    Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G: Young men with high-normal blood pressure have lower serum adiponectin, smaller LDL size, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care 25:971–976, 2002
    OpenUrlAbstract/FREE Full Text
  6. ↵
    Daimon M, Oizumi T, Saitoh T, Kameda W, Hirata A, Yamaguchi H, Ohnuma H, Igarashi M, Tominaga M, Kato T: Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in a Japanese population (Abstract). Diabetes 52 (Suppl. 1):A327, 2003
    OpenUrl
  7. ↵
    Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA, Knowler WC, Krakoff J: Adiponectin and development of type 2 diabetes in the Pima Indian population. Lancet Res Lett 360:57–58, 2002
    OpenUrl
  8. ↵
    Spranger J, Kroke A, Mohlig M, Bergmann MM, Ristow M, Boeing H, Pfeiffer AFH: Adiponectin and protection against type 2 diabetes mellitus. Lancet Res Lett 361:226–228, 2003
    OpenUrl
  9. ↵
    Banerji MA, Faridi N, Atluri R, Chaiken RL, Lebovitz HE: Body composition, visceral fat, leptin and insulin resistance in Asian Indian Men. J Clin Endocrinol Metab 84:1137–1144, 1999
    OpenUrl
  10. ↵
    Snehalatha C, Ramachandran A: Insulin resistance in Asian Indians. Prac Diab Inter 16:19–22, 1999
  11. ↵
    Ramachandran A, Snehalatha C, Mukesh B, Mary S, Vijayalakshmi J, Sathish Kumar CK, Joshi VV, Vijay V: The Indian diabetes prevention programme methodology (Abstract). In 3rd World Congress Prevention of Diabetes and its Complications: A Special WHO/IDF Workshop: Hong Kong, 29 September to 1 October 2002. A0122:P35, 2002
    OpenUrl
  12. ↵
    The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183–1197, 1997
    OpenUrlFREE Full Text
  13. ↵
    Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RL: Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412–419, 1985
    OpenUrlCrossRefPubMedWeb of Science
  14. ↵
    Hanley A, Connelly P, Harris S, Zinman B: Adiponectin in a native Canadian population experiencing rapid epidemiology transition (Abstract). Diabetes 53 (Suppl. 1):947P, 2003
    OpenUrl
  15. ↵
    Valsamakis G, Chetty R, Mc Ternan PG, Al-Daghri NM, Barnett AH, Kumar S: Fasting serum adiponectin concentration is reduced in Indo-Asian subjects and is related to HDL cholesterol. Diabetes Obes Metab 5:131–135, 2003
    OpenUrlCrossRefPubMedWeb of Science
  16. ↵
    Cnop M, Havel PJ, Utzschneider KM, Carr DB, Sinha MK, Boyko EJ, Retzlaff BM, Knopp RH, Brunzell JD, Kahn SE: Relation ship of adiponectin to body fat distribution insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex. Diabetologia 46:459–469, 2003
    OpenUrlPubMedWeb of Science
  17. Arita. Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S, Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y: Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79–83, 1999
    OpenUrlCrossRefPubMedWeb of Science
  18. ↵
    Nishizawa H. Shimonura I, Kishida K, Maeda N, Kuriyama H, Nagaretani H, Matsuda M, Kondo H, Furuyama N, Kihara S, Nakamura T, Tochino Y, Funahashi T, Matsuzawa Y: Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes 51:2734–2741, 2002
    OpenUrlAbstract/FREE Full Text
  19. ↵
    Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE, Tataranni PA: Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930–1935, 2001
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    Marcovina SM, Albers JJ, Kennedy H, Mei JV, Henderson LO, Hannon WH: International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B: IV. Comparability of apolipoprotein B values by use of international reference materials. Clin Chem 40:586–592, 1994
    OpenUrlAbstract/FREE Full Text
PreviousNext
Back to top
Diabetes Care: 26 (12)

In this Issue

December 2003, 26(12)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians
Chamukuttan Snehalatha, Bheekamchand Mukesh, Mary Simon, Vijay Viswanathan, Steven M. Haffner, Ambady Ramachandran
Diabetes Care Dec 2003, 26 (12) 3226-3229; DOI: 10.2337/diacare.26.12.3226

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian Indians
Chamukuttan Snehalatha, Bheekamchand Mukesh, Mary Simon, Vijay Viswanathan, Steven M. Haffner, Ambady Ramachandran
Diabetes Care Dec 2003, 26 (12) 3226-3229; DOI: 10.2337/diacare.26.12.3226
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Suboptimal Use of Cardioprotective Drugs in Newly Treated Elderly Individuals With Type 2 Diabetes
  • Disparities in Diabetes Care Between Smokers and Nonsmokers
  • Elevated Cystatin C Concentration and Progression to Pre-Diabetes
Show more Epidemiology/Health Services/Psychosocial Research

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.